Dirk Thye
CEO, Chief Medical Officer & Director
Greetings, everyone, and welcome to our first ever Investor Day for Quince Therapeutics. My name is Dirk Thye, and I’ll be walking you through the beginning elements of our presentation. We’ve got a full agenda for you today. I’m going to start by giving you an overview of Quince Therapeutics, our technology, our development plans and our key investment highlights.
And then I’m going to hand it over to a series of departmental and technical experts that are going to walk you through the elements of the technology itself. I’ll come back and talk about previous clinical studies and the development plan. We’ll hand it over to Caralee Schaefer to explain to you some very interesting and compelling new data on the mechanism of action of encapsulated dexamethasone.
Then we’ll talk about some elements of the regulatory plan and go into some details on our commercial planning for post-approval activities. These are some of the people you’ll be hearing from today. There are some additional team members on this slide. And the point here is to demonstrate that we’ve got a very good team of people with a lot of expertise and experience in their particular functional area.
And as I said, some of the key speakers are listed on
